Indian Cannabis for GI Disease Market size stood at USD XX billion in 2019 and is projected to reach USD XX billion by 2028, exhibiting a CAGR of XX% during the forecast period.
There are 27 million cannabis (bhang) users are in India. With an additional 16 million Indians use illegal cannabis products. Cannabis has been used to treat gastrointestinal (GI) conditions that range from enteric infections and inflammatory conditions to disorders of motility, emesis and abdominal pain. The DDS sustains the release of drugs and avails local therapy in the small intestine and stomach. The method is useful in the treatment of various disorders related to the small intestine and stomach. Rising cases of stomach and small intestine-related disorders are anticipated to foster the demand for such efficient DDSs. According to the Endoscopy Center, each year around 62.0 million people are diagnosed with digestive disorders. The prevalence of most digestive disorders increases with age, creating demand for novel healthcare systems among adults and the geriatric population. It can be especially useful for individuals taking opioid medications for abdominal pain, as research shows that cannabis helps patients cut down on or eliminate their need for opioids and provides a treatment with fewer side effects. Cannabis also helps individuals who have a difficult time eating enough by increasing appetite and it can help reduce diarrhea and nausea.
Key factors supporting the growth are the increasing legalization of marijuana for adult use and the high consumption rate in India. The growth in the demand for cannabis for GI Diseases has further propelled the need to come up with better product delivery systems as well as sustainable product strains. This need has, in turn, led to many companies coming up with R&D, which extensively investigates several genetic improvement strategies for cannabis. For instance, Hydro apothecary partnered with Segra in March 2018 to incorporate plant tissue propagation into the cannabis plant production process, to help increase the yield of healthy and better variant plants to serve the growing industry for medical and recreational cannabis. While looking into this genetic improvement, companies have been extensively venturing into the development of wide yielding varieties, better harvest ability and market quality, a reliable low THC content, and improved herbicide tolerance of the cannabis crop. The high yield potential of cannabis arises from several factors that are both genetic and agronomic in nature.